Le Cryopack 6.2/4L PSE est un conditionnement isotherme permettant l’expédition en température basse (réfrigération ou congélation) de matières infectieuses pour l’homme (matières identifiées dans la classe 6, division 6.2 des réglementations IATA, ADR et IMDG).
Objectif du module : identifier les caractéristiques du virus, ses caractères virologiques, diagnostique au laboratoire
Objectif du module : Identifier les différents virus de fièvres hémorragiques dont le virus Ebola, ses symptômes, modes de transmission et moyens de prévention
Objectif du module : Identifier un accident d'exposition au sang, les conduites à risque, la conduite à tenir, les mesures de précautions universelles.
Objectif du module : Décrire un PSM 2, travailler sous un PSM 2, identifier les bonnes pratiques de laboratoires : nettoyage, désinfection, risque des aérosols, consignes de sécurité.
Handout presentations in PDF for illustrating lectures
Accessed May 2014
Handout presentations in PDF for illustrating lectures
Accessed May 2014
The South Sudan Nutrition Cluster is a coordination mechanism which aims to ensure coherent, strategic and effective emergency nutrition responses, working with national and international partners on agreed priorities. The Cluster focuses on coordination, capacity building, emergency preparedness, a...ssessment and response, and improving coverage of emergency nutrition programs. On this website Nutrition Cluster partners can find relevant information to support their emergency nutrition activities, and interested stakeholders can find relevant information concerning the nutritional response to undernutrition in South Sudan:
https://sites.google.com/site/nutritionclustersouthsudan/
more
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
more